Education
About Us
Working with TipRanks
Follow Us
Check-Cap Ltd. (CHEK)
:CHEK
CHEK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.56 - $3.13
Previous CloseN/A
Volume282.32K
Average Volume (3M)6.22M
Market Cap
$14.95M
Enterprise ValueN/A
Total Cash (Recent Filing)$17.82M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.38
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.00
Shares Outstanding7,020,502
10 Day Avg. Volume268,116
30 Day Avg. Volume6,218,852
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Check-Cap News
CHEK FAQ
What was Check-Cap Ltd.’s price range in the past 12 months?
Check-Cap Ltd. lowest stock price was $0.56 and its highest was $3.13 in the past 12 months.
What is Check-Cap Ltd.’s market cap?
Check-Cap Ltd.’s market cap is $14.95M.
When is Check-Cap Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Check-Cap Ltd.’s earnings last quarter?
Currently, no data Available
Is Check-Cap Ltd. overvalued?
According to Wall Street analysts Check-Cap Ltd.’s price is currently Overvalued.
Does Check-Cap Ltd. pay dividends?
Check-Cap Ltd. does not currently pay dividends.
What is Check-Cap Ltd.’s EPS estimate?
Check-Cap Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Check-Cap Ltd. have?
Check-Cap Ltd. has 7,020,502 shares outstanding.
What happened to Check-Cap Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Check-Cap Ltd.?
Currently, no hedge funds are holding shares in CHEK
Company Description
Check-Cap Ltd.
Check-Cap Ltd. is a medical technology company that focuses on the development of C-Scan, an ingestible capsule-based system designed to detect polyps before they may transform into colorectal cancer. The company operates within the healthcare and medical device sectors, aiming to provide a patient-friendly, preparation-free screening option for colorectal cancer, enhancing early detection and prevention efforts.
Technical Analysis
Applied DNA Sciences
―
ENDRA Life Sciences
―
Intelligent Bio Solutions
―
Mainz Biomed B.V.
―
bioAffinity Technologies, Inc.
―
Ownership Overview
―
Insiders
0.20% Mutual Funds
0.20% Other Institutional Investors
99.60% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---